ArticleBMC cancer2015

Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.

Toshio Nishimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.